Table 1.
Baseline characteristics and comparison between two groups of patients with CHC treated with or without atorvastatin + antiviral therapy
| Variable | N (%) | Group I n (%) | Group II n (%) | P value |
|---|---|---|---|---|
| Gender, n% | ||||
| Male | 50 (71.43) | 27 (77.14) | 23 (65.71) | A0.29 |
| Female | 20 (28.57) | 8 (22.86) | 12 (34.29) | |
| Age, years, mean ± SD | ||||
| 70 | 36.37 ± 7.7 | 36.23 ± 9.1 | B0.94 | |
| Drug abuse, n (%) | ||||
| Yes | 40 (57.14) | 23 (65.71) | 17 (48.57) | A0.15 |
| No | 30 (42.86) | 12 (34.29) | 18 (51.43) | |
| Genotype n (%) | ||||
| Subtype 1 | 22 (31.43) | 10 (28.57) | 12 (34.29) | Fisher exact, 0.7 |
| Subtype 2 | 1 (1.43) | 0 | 1 (2.86) | |
| Subtype 3 | 46 (65.71) | 24 (68.57) | 22 (62.86) | |
| Subtype 4 | 1 (1.43) | 1 (2.86) | 0 | |
| Viral load, n% | ||||
| Low | 37(52.86) | 20 (57.14) | 17 (48.57) | A0.47 |
| High | 33 (47.14) | 15 (42.86) | 18 (51.43) | |
| Liver biopsy Knodell HAI, n % | ||||
| 1 | 12 (17.91) | 6 (17.65) | 6 (18.18) | C0.24 |
| 2 | 22 (32.84) | 13 (38.24) | 9 (27.27) | |
| 3 | 13 (19.4) | 8 (23.53) | 5 (15.15) | |
| 4 | 11 (16.42) | 5 (14.71) | 6 (18.18) | |
| 5 | 4 (5.97) | 1 (2.94) | 3 (9.09) | |
| 6 | 1 (1.49) | 0 | 1 (3.03) | |
| 7 | 1 (1.49) | 0 | 1 (3.03) | |
| 9 | 1 (1.49) | 1 (2.94) | 0 | |
| 11 | 1 (1.49) | 0 | 1 (3.03) | |
| 18 | 1 (1.49) | 0 | 1 (3.03) | |
| Presence of fibrosis, n% | ||||
| No fibrosis | 50 (71.43) | 28 (80) | 22 (62.86) | Fisher exact, 0.165 |
| Fibrosis present | 17 (24.29) | 7 (20) | 10 (28.57) | |
| Cirrhosis | 3 (4.29) | 0 | 3 (8.57) | |
| Steatosis, n% | ||||
| No steatosis | 32 (45.71) | 14 (40) | 18 (51.43) | Fisher exact, 0.6 |
| Mild | 34 (48.57) | 19 (54.29) | 15 (42.86) | |
| Severe | 4 (5.71) | 2 (5.71) | 2 (5.71) | |
| BMI, mean ± SD | ||||
| 25.52±4.4 | 25.77 ± 4.2 | 25.27 ± 4.6 | B0.64 | |
| AST (10-34 U/L), mean ± SD | ||||
| 72.53±75.2 | 63.6 ± 45.3 | 81.46 ± 96.3 | C0.44 | |
| ALT (10-45 U/L), mean ± SD | ||||
| 108.86±89.7 | 99.97 ± 68.9 | 117.7 ± 106.8 | C0.73 | |
| Trigliceride (0.0-2.0 mmol/L), mean ± SD | ||||
| 1.15 ± 0.6 | 1.17 ± 0.6 | 1.14 ± 0.6 | C0.9 | |
| Total Cholesterol (0.0-5.5 mmol/L), mean ± SD | ||||
| 4.27 ± 1.1 | 4.16 ± 1.3 | 4.38 ± 0.9 | C0.41 | |
| HDL-C (0.9-2.0 mmol/L), mean ± SD | ||||
| 1.15 ± 0.3 | 1.12 ± 0.3 | 1.17 ± 0.3 | C0.5 | |
| LDL-C (2.2-3.7 mmol/L), mean ± SD | ||||
| 2.54 ± 0.96 | 2.47 ± 1.1 | 2.61 ± 0.8 | C0.53 | |
| Fasting glucose (3.6-6.5 mmol/L), mean ± SD | ||||
| 5.38 ± 0.7 | 5.35 ± 0.7 | 5.41 ± 0.7 | C0.7 | |
| Fasting insulin (2-17 µiu/ml), mean ± SD | ||||
| 12.45 ± 10.8 | 12.95 ± 11.1 | 11.98 ± 10.7 | C0.72 | |
| HOMA-IR, mean ± SD | ||||
| 2.96 ± 2.7 | 3.12 ± 3.04 | 2.81 ± 2.5 | C0.67 | |
Group I (with Atorvastatin); group II (without Atorvastatin).